L309-1197 Screening compound: 4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide

L309-1197 Screening compound: 4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide
L309-1197 Screening compound: 4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L309-1197
4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L309-1197

Molecular Formula

C21H21N5O5S (C21 H21 N5 O5 S)

Compound Name

4-[(5-cyclobutyl-1,2,4-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazine-6-sulfonamide

IUPAC name

4-[(5-cyclobutyl-124-oxadiazol-3-yl)methyl]-3-oxo-N-[(pyridin-2-yl)methyl]-34-dihydro-2H-14-benzoxazine-6-sulfonamide

SMILES

O=C1N(Cc2noc(C3CCC3)n2)c(cc(cc2)S(NCc3ncccc3)(=O)=O)c2OC1

InChI

InChI=1S/C21H21N5O5S/c27-20-13-30-18-8-7-16(32(28,29)23-11-15-6-1-2-9-22-15)10-17(18)26(20)12-19-24-21(31-25-19)14-4-3-5-14/h1-2,6-10,14,23H,3-5,11-13H2

InChI Key

JEYHZYGNSLXJHQ-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27644590

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

455.49

Hydrogen Bond Acceptors Count

12.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

1.771

Distribution Coefficient, logD

1.766

Water Solubility, LogSw

-2.76

Polar Surface Area

108.561

Acid Dissociation Constant (pKa)

10.23

Base Dissociation Constant (pKb)

5.44

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

33.30

L309-1197 in Drug Discovery

Included in Screening Libraries

Nonpeptide Peptidomimetics PPI Library (18997 compounds)

Protein Kinases Inhibitors Library (36801 compounds)

Protein-Protein Interaction Library (218420 compounds)

Serine Proteases Inhibitors Library (32732 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics
Therapeutical areas:
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Nervous system
  • Hemic and lymphatic
  • Cardiovascular
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Cardiovascular
  • Skin
  • Metabolic
  • Immune system
Targets:
  • Kinases
  • Proteases

References: we are preparing a list of scientific research reports with L309-1197 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L309-1197?
Check Price and Availability of L309-1197, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L309-1197 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L309-1197
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L309-1197
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L309-1197 available by request